Sunday - October 4, 2026
Hogan Lovells Cadwalader Advises Ligand on Financing Agreement With AvenCell Therapeutics
September 30, 2026
LONDON, England, Sept. 30 -- Hogan Lovells Cadwalader, a law firm, issued the following news release:

* * *

Hogan Lovells Cadwalader advises Ligand on financing agreement with AvenCell Therapeutics

Philadelphia, Houston, 29, September 2026 - Global law firm Hogan Lovells Cadwalader has advised Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) as it enters into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company dev . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products